Research ArticleLaboratory Studies
Technetium-99m-N1-(2-Mercapto-2-Methylpropyl)-N2-(2-Propargylthio-2-Methylpropyl)-1,2-Benzenediamine (T691): Preclinical Studies of a Potential New Tracer of Regional Cerebral Perfusion
Stephan F. Taylor, Kirk A. Frey, Ronald M. Baldwin, Stephen M. Papadopoulos, Neil A. Petry, W. Leslie Rogers, Bill J. McBride, Janice M. Kerr and David E. Kuhl
Journal of Nuclear Medicine October 1992, 33 (10) 1836-1842;
Stephan F. Taylor
Kirk A. Frey
Ronald M. Baldwin
Stephen M. Papadopoulos
Neil A. Petry
W. Leslie Rogers
Bill J. McBride
Janice M. Kerr
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Technetium-99m-N1-(2-Mercapto-2-Methylpropyl)-N2-(2-Propargylthio-2-Methylpropyl)-1,2-Benzenediamine (T691): Preclinical Studies of a Potential New Tracer of Regional Cerebral Perfusion
Stephan F. Taylor, Kirk A. Frey, Ronald M. Baldwin, Stephen M. Papadopoulos, Neil A. Petry, W. Leslie Rogers, Bill J. McBride, Janice M. Kerr, David E. Kuhl
Journal of Nuclear Medicine Oct 1992, 33 (10) 1836-1842;
Technetium-99m-N1-(2-Mercapto-2-Methylpropyl)-N2-(2-Propargylthio-2-Methylpropyl)-1,2-Benzenediamine (T691): Preclinical Studies of a Potential New Tracer of Regional Cerebral Perfusion
Stephan F. Taylor, Kirk A. Frey, Ronald M. Baldwin, Stephen M. Papadopoulos, Neil A. Petry, W. Leslie Rogers, Bill J. McBride, Janice M. Kerr, David E. Kuhl
Journal of Nuclear Medicine Oct 1992, 33 (10) 1836-1842;
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.